+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Latin America Cancer Biomarker Market 2019-2025

  • PDF Icon

    Report

  • February 2020
  • Region: Latin America
  • Orion Market Research Private Limited
  • ID: 5116752
UP TO OFF until Dec 31st 2022
Latin America Cancer Biomarker Market Size, Share & Trends Analysis Report by Biomarker Type (Genetic Biomarker, and Protein Biomarker), by Cancer Type (Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, and Other), by Applications (Drug Discovery and Development, Diagnosis, Risk Assessment, and Prognostics), and by Profiling Technology (Omics Technology, Immunoassays, Cytogenetics, and Bioinformatics) Forecast Period 2019-2025.

Latin America cancer biomarkers market is growing at a CAGR of around 11.1% during the forecast period. The significant increase in prevalence of cancer is the major factor behind fueling the Latin America cancer biomarker market. Change in life style, vulnerability to various infectious disease, lack of awareness about the disease and lack of infrastructure are the major reason attributed for the prevalence of cancer.

The key driving factors for the growth of the Latin America cancer biomarker market include rise in the number of cancer cases. Due to rise in the number of cases, there has been an increasing demand for highly effective chemotherapeutic agents which in turn drives the market. In Latin America, the estimates show there will 72% rise in incidence of cancer in men and 62% in women by 2030. The major cause behind the malignant disease is living more sedentary lifestyle, smoking, and consumption of unhealthy food in Latin America. The prevalence of prostate cancer is highest, and it has increased significantly from 477,000 to 540,402, with 3 years from 2014-2016. Prostate cancer leads to highest deaths in the region. Breast cancer follows the former type, it is attributable for second largest amount of death due to cancer, the prevalence rate has also increased in the same pace. The other types of cancer have prevailed but not significantly in past few years.

The Latin American region is growing with a positive pace in cancer biomarker market owing to advancement in medical healthcare facilities which encourage the diagnostics of the cancers. Government support and involvement of WHO from the last two decades enable to promote awareness and promoted health coverage (Insurance) in low-middle income countries. The government in Latin America is continuously investing around 6.2% of their GDP in the healthcare sector. Breast cancer is the most common cancer and leading cause of cancer deaths in women of Latin America. Several countries exhibit some of the highest mortality rates in the world, highlighting the health disparities in the region. Earlier diagnosis in addition to the advances in treatment has led to better outcomes and longer survival for women with breast cancer. Thus, it will contribute to the Latin America cancer biomarker market growth during the forecast period.

Research Methodology:

The market study of the Latin American cancer biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for biotechnology companies, research laboratories, pharmaceutical companies, research institutions, hospitals, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Latin America Cancer Biomarker Market Research and Analysis by Biomarker Type
2. Latin America Cancer Biomarker Market Research and Analysis by Cancer Type
3. Latin America Cancer Biomarker Market Research and Analysis by Application

4. Latin America Cancer Biomarker Market Research and Analysis by Profiling Technology

The Report Covers:
  • Comprehensive Research Methodology of the Latin America Cancer biomarker market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Latin America Cancer biomarker market.
  • Insights about market determinants which are stimulating the Latin America Cancer biomarker market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories Inc.
  • Astellas Pharma Inc.
  • Becton, Dickson and Co.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd.
  • Merck and Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • QIAGEN GmbH
  • Thermo Fisher Scientific Inc.